The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis
Horm Metab Res 2022; 54: 458-471 DOI: 10.1055/a-1844-1176Aim To determine the antiobesity effect and safety of glucagon-like
peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and
semaglutide treatment in overweight/obese patients without diabetes. The
random-effect model was used to pool data extracted from included literatures.
The weighted mean difference (WMD), odds ratio and 95% confidence
interval (CI) were used to present the meta-analysis results (PROSPERO
registration number: CRD 42020173199). The sources of intertrial heterogeneity,
bias and the robustness of results were evaluated by subgroup analysis,
sensitivity analysis and regression analysis, respectively. A total of 24 RCTs
were recruited in the present analysis which included 5867 patients. The results
showed that the treatment of overweight/obese patients without diabetes
with GLP-1RAs including liraglutide, exenatide and semaglutide significantly
achieved greater weight loss than placebo [WMD=–5.39,
95% CI (–6.82, –3.96)] and metformin
[WMD=–5.46, 95% CI (–5.87, –5.05)]. The
subgroup analysis showed that semaglutide displayed the most obvious antiobesity
effect in terms of weight loss, the reduction of body mass index (BMI) and waist
circumference (WC). However, GLP-1RAs treatments had more gastrointestinal...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Guo, Xiaonan Zhou, Zhibo Lyu, Xiaorui Xu, Hanyuan Zhu, Huijuan Pan, Hui Wang, Linjie Yang, Hongbo Gong, Fengying Tags: Original Article: Endocrine Care Source Type: research
More News: Byetta | Diabetes | Eating Disorders & Weight Management | Endocrinology | Fortamet | Gastroenterology | Hormones | Metformin | Obesity | Victoza | Weight Loss